« More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone. »
Ropeginterferon Alfa-2b Helps Maintain Hematocri... - MPN Voice
Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Should ropeginterferon become SoC for all patients with low-risk PV?
Can’t wait to have this in the US
Not what you're looking for?
You may also like...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
available for patients with polycythemia vera, the FDA has requested additional information. »...
Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
low-risk polycythemia vera, irrespective of treatment history....
FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera
application for ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia......
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
What were the results?
Over a lifetime, the model showed that patients who received...
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
need for phlebotomy or erythrocyte apheresis. The CHRs were very durable and the levels of CHR were...
Related Posts
- Interferon-Alpha Reduces Myelofibrosis Risk, Mortality Rate in Low- and High-Risk Polycythemia Vera
- Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
- Long-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
- The Gut Microbiota in Patients with Polycythemia Vera is Distinct from that of Healthy Controls and Varies by Treatment
Increasing evidence that Interferons are our best treatment option for PV
